A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Wugen, Inc.
Wugen, Inc.
Kura Oncology, Inc.
Novartis
Novartis
Incyte Corporation
Amgen
Janssen Research & Development, LLC
Janssen Research & Development, LLC
TScan Therapeutics, Inc.
Gilead Sciences
AstraZeneca
medac GmbH